ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

$40 million for boron neutron capture therapy

by Ryan Cross
March 19, 2018 | APPEARED IN VOLUME 96, ISSUE 12

TAE Life Sciences has raised $40 million in series A funding and launched as a subsidiary of the nuclear fusion energy company TAE Technologies. TAE Life Sciences aims to commercialize a cancer radiation treatment called boron neutron capture therapy. In BNCT, boron-10 is administered to tumors, irradiated with a beam of neutrons, and broken down into charged particles that kill cancer cells. The concept was first tested in humans in the 1950s but was slow to take off. TAE says its accelerator-based technology will make neutrons for BNCT more accessible in hospitals.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment